NCT04691375 - A Study of PY314 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

August 31, 2023

Study Completion Date

September 22, 2023

Conditions

Advanced Solid TumorGynecologic CancerBreast CancerColorectal CancerLung AdenocarcinomaRenal Cell CarcinomaTriple Negative Breast CancerHormone Receptor/Growth Factor Receptor-Negative Breast CancerOvarian Cancer

Interventions

DRUG

PY314

Dose of PY314 as a single agent given in a standard 3+3 design.

DRUG

Combination Therapy: PY314 + Pembrolizumab

Dose of PY314 alone and given in combination with pembrolizumab

Trial Locations (23)

10029

Icahn School of Medicine at Mount Sinai, New York

19107

Thomas Jefferson University, Philadelphia

22031

NEXT Virginia, Fairfax

32224

Mayo Clinic Jacksonville - PPDS, Jacksonville

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt Ingram Cancer Center, Nashville

44195

The Cleveland Clinic Foundation, Cleveland

48201

Karmanos Cancer Institute, Detroit

53705

Wisconsin Institutes for Medical Research, Madison

55905

Mayo Clinic - PPDS, Rochester

60637

University of Chicago, Chicago

73104

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City

78229

Start South Texas Accelerated Research Therapeutics, San Antonio

80045

University of Colorado Hospital, Aurora

85054

Mayo Clinic Scottsdale - PPDS, Phoenix

91010

City of Hope - Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, San Diego

94304

Stanford Hospital and Clinics, Palo Alto

97239

OHSU Knight Cancer Institute Beaverton Clinic, Portland

85258-4566

Honor Health Research Institute, Scottsdale

02214

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston